Publication: Epidemiology, approach and management of functional dyspepsia in Thailand
Issued Date
2011-01-01
Resource Type
ISSN
14401746
08159319
08159319
Other identifier(s)
2-s2.0-79953081425
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Gastroenterology and Hepatology (Australia). Vol.26, No.SUPPL. 3 (2011), 32-34
Suggested Citation
Udom Kachintorn Epidemiology, approach and management of functional dyspepsia in Thailand. Journal of Gastroenterology and Hepatology (Australia). Vol.26, No.SUPPL. 3 (2011), 32-34. doi:10.1111/j.1440-1746.2011.06647.x Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/12724
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Epidemiology, approach and management of functional dyspepsia in Thailand
Author(s)
Other Contributor(s)
Abstract
Background and aim: Functional dyspepsia (FD) represents one of the important GI disorders confronting clinicians worldwide including Thailand. FD is a clinical syndrome with various underlying pathophysiologies, and their treatment remains a major challenge. This article aims at the approach of FD and its management. Method: For current situation, optimal therapy includes non-drug therapy namely reassurance by ruling out relevant differential diagnoses, general advice with regard to the underlying causes, dietary measures, lifestyle modification, and good doctor-patient relationship. Removing precipitating causes, such as medications, food or psychological factors/stress contributing to symptoms, is mandatory. A wide variety of drug treatments have been used to manage FD including antisecretory agents, prokinetics and H.pylori eradication. Results: It is understandable that there is no ideal drug available. The overall gain over placebo ranges from less than 5% for H.pylori eradication to 15%-20% for antisecretory agents and prokinetics. Conclusion: Drug therapy includes acid inhibitory agents, prokinetics and H.pylori eradication are still the mainstay and should be adjusted accordingly on a case-by-case basis. In the future, it would be logical to develop multi-target therapies that simultaneously address various underlying mechanisms. © 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.
